Skip to main content

Table 5 Baseline characteristics of patients with LS-SCLC and ILA in this study

From: Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

Variable First-line treatment
Chemoradiotherapy Chemotherapy P value
(n = 25) (n = 24)
Age, ≥ 70/ < 70 years 16/9 18/6 0.5380
Sex, male/female 21/4 20/4 1.0000
ECOG-PS, 0/1/2 (0 vs. 1 or 2) 15/10/0 10/11/3 0.2578
Clinical stagea, I/II/III (I vs. II/III) 1/1/23 1/5/18 1.0000
Brinkmann index, ≥ 400/ < 400 24/1 23/1 1.0000
Proportion of ILA area of any lung zone, 5%/10%/15–30%/30–50% (5%/10% vs. 15–30%/30–50%) 13/11/1/0 9/7/7/1 0.0106
V20, median (range), % 22 (10–32)   
  1. aClinical staging was according to the 7th edition of the TNM classification of lung cancer [9]. LS-SCLC, limited-stage small-cell lung cancer
  2. ECOG-PS, Eastern Cooperative Oncology Group performance status; ILA, interstitial lung abnormality; V20, percentage of normal lung receiving at least 20 Gy